AbbVie delivered a strong start to 2026, exceeding expectations with robust revenue growth driven by its key immunology and neuroscience portfolios. The company raised its full-year adjusted EPS guidance, reflecting confidence in its ongoing performance and pipeline advancements.
First-quarter net revenues increased 12.4% on a reported basis to $15.002 billion, or 10.3% operationally.
positiveImmunology portfolio net revenues grew 16.4% reported to $7.290 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%.
positiveNeuroscience portfolio net revenues increased 26.0% reported to $2.875 billion, led by strong growth in Vraylar and Botox Therapeutic.
positiveFull-year 2026 adjusted diluted EPS guidance raised to $14.08 - $14.28 from $13.96 - $14.16.
positiveAdjusted diluted EPS of $2.65 increased 7.7% year-over-year, exceeding expectations.
positiveGAAP diluted EPS decreased 45.8% to $0.39, significantly impacted by $0.41 per share from acquired IPR&D and milestones expense.
attentionOncology portfolio net revenues decreased 0.2% reported to $1.631 billion, with Imbruvica down 24.7%.
attentionHumira net revenues decreased 38.6% reported to $688 million, indicating continued erosion.
attentionAcquired IPR&D and milestones expense was $744 million, a significant increase from $248 million in the prior year.
attentionJuvederm Collection net revenues decreased 2.9% operationally.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Immunology | N/A | — | — | — | +14.3% |
Neuroscience | N/A | — | — | — | +24.3% |
Oncology | N/A | — | — | — | -3.0% |
Aesthetics | N/A | — | — | — | +5.1% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.
We are also generating exciting data and advancing numerous programs across all stages of development.
Our pipeline progress and solid business fundamentals position AbbVie for robust long-term growth.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.